Researchers found that a new combination treatment may significantly extend the lifespan of aged mice. This therapy, known as SRN-901, combines several well-known supplements, including urolithin A, quercetin, nicotinamide riboside, and alpha-lipoic acid. In a study funded by the company Seragon, mice treated with SRN-901 experienced a remarkable 33% increase in median remaining lifespan compared to those receiving a placebo. Additionally, the treatment reduced frailty and improved metabolic health, suggesting it could have broader implications for aging.

This discovery is particularly relevant for anyone interested in healthy aging. The results indicate that SRN-901 not only prolongs life but also enhances quality of life by reducing frailty, a common concern for older adults. The study involved 24 to 44 mice per group, providing a solid foundation for these findings. A 46% reduction in the risk of death among treated mice highlights the potential of this combination therapy to improve longevity and vitality as we age.

However, it’s important to approach these results with caution. The research is still in its early stages, focusing on animal models rather than humans. While the outcomes are promising, more studies are needed to confirm these effects in people and to understand the specific roles of each component in the treatment. As with any new health intervention, waiting for further evidence before making changes to your regimen is wise.

Source: fightaging.org